Fetal growth promoting effect of hydroxyethylrutoside in pregnant women

Éva Pósfai, E. Czeizel, F. Bánhidy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective. To evaluate the effect of hydroxyethylrutoside (HER) for fetal development because this flavonoid derivate drug is frequently used in pregnant women for the treatment of vascular diseases. Method. Comparative analysis of exposure (HER treatment) during pregnancy in the newborn infants without any defects born to mothers with or without HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Main outcomes measures were gestational age at delivery, birth weight, pre- and post-term birth, low and large birth weight. Results: Of 38,151 newborn infants, 1,143 (3.0%) were born to mothers with oral HER treatment. The mean birth weight of newborn infants born to mothers with HER was 115 grams larger and is associated with a lower rate of low birth weight and a higher rate of large birth weight. Conclusions. Oral HER treatment during pregnancy associates with a fetal growth promotion effect.

Original languageEnglish
Pages (from-to)802-806
Number of pages5
JournalCentral European Journal of Medicine
Volume9
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Hydroxyethylrutoside
Fetal Development
Pregnant Women
Birth Weight
Mothers
Low Birth Weight Infant
Newborn Infant
Term Birth
Therapeutics
Pregnancy
Vascular Diseases
Flavonoids
Gestational Age
Outcome Assessment (Health Care)

Keywords

  • Birth weigh
  • Fetal growth promotion
  • Gestational age at delivery
  • Hydroxyethylrutoside
  • Low birthweight
  • Population-based study
  • Pregnancy
  • Preterm birth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fetal growth promoting effect of hydroxyethylrutoside in pregnant women. / Pósfai, Éva; Czeizel, E.; Bánhidy, F.

In: Central European Journal of Medicine, Vol. 9, No. 6, 2014, p. 802-806.

Research output: Contribution to journalArticle

@article{1604525046ef4e34b0b636cd9abccf12,
title = "Fetal growth promoting effect of hydroxyethylrutoside in pregnant women",
abstract = "Objective. To evaluate the effect of hydroxyethylrutoside (HER) for fetal development because this flavonoid derivate drug is frequently used in pregnant women for the treatment of vascular diseases. Method. Comparative analysis of exposure (HER treatment) during pregnancy in the newborn infants without any defects born to mothers with or without HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Main outcomes measures were gestational age at delivery, birth weight, pre- and post-term birth, low and large birth weight. Results: Of 38,151 newborn infants, 1,143 (3.0{\%}) were born to mothers with oral HER treatment. The mean birth weight of newborn infants born to mothers with HER was 115 grams larger and is associated with a lower rate of low birth weight and a higher rate of large birth weight. Conclusions. Oral HER treatment during pregnancy associates with a fetal growth promotion effect.",
keywords = "Birth weigh, Fetal growth promotion, Gestational age at delivery, Hydroxyethylrutoside, Low birthweight, Population-based study, Pregnancy, Preterm birth",
author = "{\'E}va P{\'o}sfai and E. Czeizel and F. B{\'a}nhidy",
year = "2014",
doi = "10.2478/s11536-013-0347-2",
language = "English",
volume = "9",
pages = "802--806",
journal = "Central European Journal of Medicine",
issn = "1895-1058",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Fetal growth promoting effect of hydroxyethylrutoside in pregnant women

AU - Pósfai, Éva

AU - Czeizel, E.

AU - Bánhidy, F.

PY - 2014

Y1 - 2014

N2 - Objective. To evaluate the effect of hydroxyethylrutoside (HER) for fetal development because this flavonoid derivate drug is frequently used in pregnant women for the treatment of vascular diseases. Method. Comparative analysis of exposure (HER treatment) during pregnancy in the newborn infants without any defects born to mothers with or without HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Main outcomes measures were gestational age at delivery, birth weight, pre- and post-term birth, low and large birth weight. Results: Of 38,151 newborn infants, 1,143 (3.0%) were born to mothers with oral HER treatment. The mean birth weight of newborn infants born to mothers with HER was 115 grams larger and is associated with a lower rate of low birth weight and a higher rate of large birth weight. Conclusions. Oral HER treatment during pregnancy associates with a fetal growth promotion effect.

AB - Objective. To evaluate the effect of hydroxyethylrutoside (HER) for fetal development because this flavonoid derivate drug is frequently used in pregnant women for the treatment of vascular diseases. Method. Comparative analysis of exposure (HER treatment) during pregnancy in the newborn infants without any defects born to mothers with or without HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Main outcomes measures were gestational age at delivery, birth weight, pre- and post-term birth, low and large birth weight. Results: Of 38,151 newborn infants, 1,143 (3.0%) were born to mothers with oral HER treatment. The mean birth weight of newborn infants born to mothers with HER was 115 grams larger and is associated with a lower rate of low birth weight and a higher rate of large birth weight. Conclusions. Oral HER treatment during pregnancy associates with a fetal growth promotion effect.

KW - Birth weigh

KW - Fetal growth promotion

KW - Gestational age at delivery

KW - Hydroxyethylrutoside

KW - Low birthweight

KW - Population-based study

KW - Pregnancy

KW - Preterm birth

UR - http://www.scopus.com/inward/record.url?scp=84907357398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907357398&partnerID=8YFLogxK

U2 - 10.2478/s11536-013-0347-2

DO - 10.2478/s11536-013-0347-2

M3 - Article

AN - SCOPUS:84907357398

VL - 9

SP - 802

EP - 806

JO - Central European Journal of Medicine

JF - Central European Journal of Medicine

SN - 1895-1058

IS - 6

ER -